Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model
ABSTRACT IMC‐002, an anti‐cluster of differentiation 47 (CD47) antibody, was developed as a fully human immunoglobulin (Ig) G4 monoclonal antibody targeting CD47. IMC‐002 blocks CD47–signal regulatory protein alpha (SIRPα) interactions, increasing the phagocytosis of cancer cells by macrophages. Thi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70321 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227162791444480 |
|---|---|
| author | Seongmee Jeong Sung Young Lee Sung Ho Kim Heung Tae Kim Hwi‐yeol Yun Jung‐woo Chae Soyoung Lee |
| author_facet | Seongmee Jeong Sung Young Lee Sung Ho Kim Heung Tae Kim Hwi‐yeol Yun Jung‐woo Chae Soyoung Lee |
| author_sort | Seongmee Jeong |
| collection | DOAJ |
| description | ABSTRACT IMC‐002, an anti‐cluster of differentiation 47 (CD47) antibody, was developed as a fully human immunoglobulin (Ig) G4 monoclonal antibody targeting CD47. IMC‐002 blocks CD47–signal regulatory protein alpha (SIRPα) interactions, increasing the phagocytosis of cancer cells by macrophages. This study established a target‐mediated drug disposition (TMDD) pharmacokinetics (PK) model for IMC‐002 to explain the characteristics of the neonatal Fc receptor (FcRn) of IgG based on phase Ia trial data to perform model‐informed optimal dosing for a phase Ib study. The PK data were obtained from a phase Ia dose escalation study on 12 patients with advanced solid tumors. Each patient received multiple doses (5, 10, 20, or 30 mg/kg) via intravenous infusion over 3 h every 2 weeks. The IMC‐002 PK data were analyzed using NONMEM software (version 7.5) using the first‐order conditional estimation method with interaction (FOCEI). The semi‐mechanistic TMDD model explained the nonlinear PK properties of IMC‐002, including FcRn recirculation. Weight, sex, and age were investigated as covariates using stepwise covariate testing. No statistical covariates were identified. Simulations were performed to determine the optimal dosing regimen for patients with solid tumors that extend the administration period and maintain the mean concentrations above the minimum effective concentration (MEC). The ideal regimen of 20 mg/kg every 3 weeks ensured that the mean plasma concentration remained above the MEC throughout the dosing interval. Our study developed a robust TMDD PK model for IMC‐002, which provides the rationale for a dose regimen in a phase 1b study. |
| format | Article |
| id | doaj-art-7f77d204eba64ed58ab8a635c2302174 |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-7f77d204eba64ed58ab8a635c23021742025-08-23T17:10:42ZengWileyClinical and Translational Science1752-80541752-80622025-08-01188n/an/a10.1111/cts.70321Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition ModelSeongmee Jeong0Sung Young Lee1Sung Ho Kim2Heung Tae Kim3Hwi‐yeol Yun4Jung‐woo Chae5Soyoung Lee6College of Pharmacy, Chungnam National University Daejeon Republic of KoreaImmuneOncia Therapeutics, Inc. Seoul Republic of KoreaImmuneOncia Therapeutics, Inc. Seoul Republic of KoreaImmuneOncia Therapeutics, Inc. Seoul Republic of KoreaCollege of Pharmacy, Chungnam National University Daejeon Republic of KoreaCollege of Pharmacy, Chungnam National University Daejeon Republic of KoreaCollege of Pharmacy, Chungnam National University Daejeon Republic of KoreaABSTRACT IMC‐002, an anti‐cluster of differentiation 47 (CD47) antibody, was developed as a fully human immunoglobulin (Ig) G4 monoclonal antibody targeting CD47. IMC‐002 blocks CD47–signal regulatory protein alpha (SIRPα) interactions, increasing the phagocytosis of cancer cells by macrophages. This study established a target‐mediated drug disposition (TMDD) pharmacokinetics (PK) model for IMC‐002 to explain the characteristics of the neonatal Fc receptor (FcRn) of IgG based on phase Ia trial data to perform model‐informed optimal dosing for a phase Ib study. The PK data were obtained from a phase Ia dose escalation study on 12 patients with advanced solid tumors. Each patient received multiple doses (5, 10, 20, or 30 mg/kg) via intravenous infusion over 3 h every 2 weeks. The IMC‐002 PK data were analyzed using NONMEM software (version 7.5) using the first‐order conditional estimation method with interaction (FOCEI). The semi‐mechanistic TMDD model explained the nonlinear PK properties of IMC‐002, including FcRn recirculation. Weight, sex, and age were investigated as covariates using stepwise covariate testing. No statistical covariates were identified. Simulations were performed to determine the optimal dosing regimen for patients with solid tumors that extend the administration period and maintain the mean concentrations above the minimum effective concentration (MEC). The ideal regimen of 20 mg/kg every 3 weeks ensured that the mean plasma concentration remained above the MEC throughout the dosing interval. Our study developed a robust TMDD PK model for IMC‐002, which provides the rationale for a dose regimen in a phase 1b study.https://doi.org/10.1111/cts.70321anti‐CD47 antibodymodel‐informed optimal dosingtarget‐mediated drug disposition model (TMDD) |
| spellingShingle | Seongmee Jeong Sung Young Lee Sung Ho Kim Heung Tae Kim Hwi‐yeol Yun Jung‐woo Chae Soyoung Lee Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model Clinical and Translational Science anti‐CD47 antibody model‐informed optimal dosing target‐mediated drug disposition model (TMDD) |
| title | Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model |
| title_full | Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model |
| title_fullStr | Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model |
| title_full_unstemmed | Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model |
| title_short | Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model |
| title_sort | model informed optimal dosing of anti cd47 antibody using target mediated drug disposition model |
| topic | anti‐CD47 antibody model‐informed optimal dosing target‐mediated drug disposition model (TMDD) |
| url | https://doi.org/10.1111/cts.70321 |
| work_keys_str_mv | AT seongmeejeong modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel AT sungyounglee modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel AT sunghokim modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel AT heungtaekim modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel AT hwiyeolyun modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel AT jungwoochae modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel AT soyounglee modelinformedoptimaldosingofanticd47antibodyusingtargetmediateddrugdispositionmodel |